Abiopharma

CO-DIAGNOSTICS, INC. (CODX)

Symbol	CODX
Name	CO-DIAGNOSTICS, INC.
Sector	HEALTH CARE
Region	North America
Industry	-
Address	84108 United States UT 2401 S. Foothill Drive Suite D
Telephone	(801) 438-1036
Fax	—
Email	—
Website	https://co-dx.com/
Incorporation	US
Incorporated On	2013
Employees	—
Fiscal Year	12/31
Public Since	—
Exchanges	OTC;NASDAQ
Auditor	Tanner LLC;
Audit Status	AUDITED
Reporting Status	U.S. Reporting: SEC Reporting
CIK	0001692415
Description	Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Additional info from OTC: Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Additional info from NASDAQ: Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDIs low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV. The companys diagnostics systems enable very rapid, low-cost, sophisticated molecular testing for organisms and genetic diseases by greatly automating historically complex procedures in both the development and administration of tests.

2026-04-30 13:00

Co-Diagnostics Announces First Quarter 2026 Earnings Release Date and Webcast

2026-03-31 20:05

(30% Negative) CO-DIAGNOSTICS, INC. (CODX) Reports Q1 2026 Financial Results

2026-03-10 13:25

(99% Neutral) CO-DIAGNOSTICS, INC. (CODX) Reports Q1 2026 Financial Results

2026-02-11 12:02

New Form SCHEDULE 13G/A - Co-Diagnostics, Inc. Filed: 2026-02-11 AccNo: 0001493152-26-006144 Size: 11 KB

2026-01-14 08:55

Co-Diagnostics Inc (CODX) was removed from the list of traded instruments on NASDAQ exchange

2026-01-14 08:36

NASDAQ symbol attribute type Security_Name was changed. Previous value: Co-Diagnostics, Inc. - Common Stock. New value: Co-Diagnostics, Inc. - Common Stock.

2026-01-14 08:36

NASDAQ symbol attribute type Financial_Status was changed. Previous value: N. New value: Co-Diagnostics, Inc. - Common Stock.

2026-01-14 08:36

NASDAQ symbol attribute type Test_mode was changed. Previous value: N. New value: Co-Diagnostics, Inc. - Common Stock.

2026-01-14 03:53

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

2026-01-14 00:38

NASDAQ traded attribute type Test_mode was changed. Previous value: N. New value: Co-Diagnostics, Inc. - Common Stock.

No clinical trials found for this company.

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
gadobenate dimeglumine	DRUG	Phase PHASE3	Central Nervous System Diseases	TERMINATED	NCT00323310
Isovue 250	DRUG	Phase PHASE4	Peripheral Arterial Occlusive Disease	COMPLETED	NCT00740207
VISIPAQUE 270	DRUG	Phase PHASE4	Peripheral Arterial Occlusive Disease	COMPLETED	NCT00740207
Gadopentetate Dimeglumine	DRUG	Phase PHASE3	Carotid, Aortic, Renal or Peripheral Artery Disease	COMPLETED	NCT01260636
GADOVIST	DRUG	Phase PHASE4	Brain Lesions	COMPLETED	NCT00907530
MULTIHANCE:	DRUG	Phase PHASE4	Brain Lesions	COMPLETED	NCT00907530
Iopamidol injection 76%	DRUG	Phase PHASE4	Chronic Renal Impairment	TERMINATED	NCT00782639
Iopamidol 370 mgI/mL	DRUG	Phase PHASE4	Contrast Induced Nephropathy	COMPLETED	NCT00292487
ultrasound guided systematic biopsy	PROCEDURE	Phase PHASE3	Prostate Cancer	TERMINATED	NCT00911027
Contrast-enhanced ultrasound guided biopsy	DRUG	Phase PHASE3	Prostate Cancer	TERMINATED	NCT00911027
CardioGen-82	DRUG	Preclinical	Radiation Exposure	COMPLETED	NCT01430975
Isovue 370, 90 mL	DRUG	Phase PHASE2	Coronary Artery Disease	COMPLETED	NCT00558792
Isovue 370, 80 mL	DRUG	Phase PHASE2	Coronary Artery Disease	COMPLETED	NCT00558792
Isovue 370, 70 mL	DRUG	Phase PHASE2	Coronary Artery Disease	COMPLETED	NCT00558792
iodixanol	DRUG	Phase PHASE4	Chronic Renal Impairment	TERMINATED	NCT00782639
iopamidol	DRUG	Phase PHASE4	Peripheral Arterial Occlusive Disease	COMPLETED	NCT01075217
Non ionic contrast media comparator	DRUG	Phase PHASE4	Coronary Artery Stenosis	COMPLETED	NCT01137786
Iodixanol 320	DRUG	Phase PHASE4	Coronary Artery Stenosis	TERMINATED	NCT01136915
Iopamidol 370	DRUG	Phase PHASE4	Coronary Artery Stenosis	TERMINATED	NCT01136915
PET imaging	OTHER	Preclinical	Coronary Artery Disease	COMPLETED	NCT01179230
SPECT imaging	OTHER	Preclinical	Coronary Artery Disease	COMPLETED	NCT01179230
DCE MRI	OTHER	Approved	Metastatic Liver Cancer	COMPLETED	NCT02201797
gadobutrol	DRUG	Phase PHASE4	Brain Disease	COMPLETED	NCT01613417
gadoteridol	DRUG	Phase PHASE4	Brain Disease	COMPLETED	NCT01613417
Gadobenate Dimeglumine	DRUG	Phase PHASE3	Carotid, Aortic, Renal or Peripheral Artery Disease	COMPLETED	NCT01260636
Placebo	DRUG	Phase PHASE2	Pulmonary Hypertension	COMPLETED	NCT01306292
SonoVue	DRUG	Phase PHASE2	Pulmonary Hypertension	COMPLETED	NCT01306292
MultiHance 0.05 mmol/kg	DRUG	Phase PHASE4	Brain Disease	COMPLETED	NCT02070380
Dotarem	DRUG	Phase PHASE4	Brain Disease	COMPLETED	NCT02070380
MultiHance 0.1 mmol/kg	DRUG	Phase PHASE4	Brain Disease	COMPLETED	NCT02070380
Iomeron	OTHER	Phase PHASE4	Aortic Disorders	COMPLETED	NCT02596048
gadobenate dimeglumine (MultiHance)	DRUG	Approved	Hepatocellular Carcinoma	COMPLETED	NCT00539253
Unenhanced ultrasound	OTHER	Phase PHASE3	Liver Neoplasms	COMPLETED	NCT00788697
SonoVue-enhanced ultrasound	DRUG	Phase PHASE3	Liver Neoplasms	COMPLETED	NCT00788697
Comprehensive Cardiothoracic CT arm	RADIATION	Phase PHASE4	Chest Pain Syndrome	COMPLETED	NCT01067456
MultiHance	DRUG	Preclinical	Central Nervous System Diseases	COMPLETED	NCT03147989
SonoVue®	DRUG	Phase PHASE3	Liver Neoplasms	COMPLETED	NCT00829413
MRI	DEVICE	Approved	Disorder of Nipple	TERMINATED	NCT02818946
ProHance	DRUG	Preclinical	Central Nervous System Diseases	COMPLETED	NCT03750188
sulphur hexafluoride lipid-type A microspheres	DRUG	Phase PHASE3	Heart Disease	TERMINATED	NCT02282163
Surgery	PROCEDURE	Preclinical	Gadolinium Retention	COMPLETED	NCT03108378
Iodixanol-320	DRUG	Phase PHASE4	Coronary Artery Stenosis	COMPLETED	NCT01136876
Arm 2 - Magnevist	DRUG	Phase PHASE4	Brain Tumor	COMPLETED	NCT00395863
Multihance	DRUG	Phase PHASE4	Brain Tumor	COMPLETED	NCT00395863
Iopamidol	DRUG	Phase PHASE4	Coronary Artery Stenosis	COMPLETED	NCT01136876
BR55	DRUG	Phase PHASE1	Prostate Cancer	COMPLETED	NCT02142608
Sulfur hexafluoride lipid-type A microspheres	DRUG	Phase PHASE3	Necrotizing Enterocolitis of Newborn	TERMINATED	NCT03549507
Dynamic Contrast-Enhanced Ultrasound Imaging	PROCEDURE	Approved	Liver Cirrhosis	COMPLETED	NCT03318380
Gadobenate dimeglumine	DRUG	Phase PHASE4	Oligometastatic Disease	TERMINATED	NCT04973007
Gadoxetate disodium	DRUG	Phase PHASE4	Oligometastatic Disease	TERMINATED	NCT04973007
Isovue	DRUG	Phase PHASE4	Hypothyroidism	TERMINATED	NCT03779906
Lumason	DRUG	Phase PHASE3	Coronary Artery Disease	COMPLETED	NCT02522481
Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]	DRUG	Phase PHASE3	Heart Diseases	RECRUITING	NCT06400004

Total products: 53